|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Nov 25 | Option Exercise | 16.77 | 8,878 | 148,884 | 32,418 | Nov 29 08:08 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Nov 25 | Sale | 23.50 | 8,878 | 208,633 | 23,540 | Nov 29 08:08 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Aug 26 | Option Exercise | 15.71 | 5,000 | 78,550 | 23,540 | Aug 30 07:18 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Aug 01 | Sale | 23.02 | 7,000 | 161,124 | 18,540 | Aug 03 08:04 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Dec 02 | Option Exercise | 8.50 | 16,109 | 136,926 | 42,963 | Dec 03 07:13 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Dec 02 | Sale | 22.00 | 16,109 | 354,398 | 26,854 | Dec 03 07:13 PM |
QDEL | TAMERIUS JOHN | SVP, Strat & Ext Affairs | Dec 01 | Sale | 21.78 | 5,000 | 108,921 | 26,854 | Dec 03 07:13 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Aug 20 | Option Exercise | 12.23 | 11,000 | 134,530 | 31,854 | Aug 24 04:36 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jul 31 | Option Exercise | 12.63 | 100 | 1,263 | 20,954 | Aug 03 06:16 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jul 30 | Option Exercise | 12.63 | 6,309 | 79,683 | 24,363 | Aug 03 06:16 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jul 30 | Sale | 21.04 | 6,309 | 132,755 | 20,854 | Aug 03 06:16 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jul 31 | Sale | 21.06 | 100 | 2,106 | 20,854 | Aug 03 06:16 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Oct 03 | Option Exercise | 8.50 | 5,000 | 42,500 | 20,766 | Oct 09 07:48 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Oct 03 | Sale | 28.00 | 5,000 | 140,000 | 15,766 | Oct 09 07:48 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Sep 18 | Option Exercise | 8.50 | 10,000 | 85,000 | 25,766 | Sep 19 07:02 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Sep 18 | Sale | 26.50 | 10,000 | 265,000 | 15,766 | Sep 19 07:02 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jul 23 | Sale | 24.50 | 15,000 | 367,500 | 15,766 | Jul 25 07:09 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Jun 24 | Sale | 23.06 | 5,000 | 115,320 | 30,766 | Jun 26 07:08 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 26 | Option Exercise | 14.25 | 22,782 | 324,548 | 54,801 | Feb 26 08:04 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 26 | Sale | 27.82 | 22,782 | 633,766 | 32,019 | Feb 26 08:04 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 25 | Sale | 27.57 | 24,464 | 674,375 | 32,019 | Feb 26 08:04 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 28 | Option Exercise | 8.09 | 28,852 | 233,523 | 57,426 | Mar 01 08:25 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 21 | Sale | 22.33 | 1,300 | 29,032 | 53,274 | Feb 22 09:22 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 22 | Sale | 22.40 | 24,700 | 553,364 | 28,574 | Feb 22 09:22 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Dec 07 | Option Exercise | 3.19 | 9,000 | 28,710 | 51,214 | Dec 11 08:33 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Dec 04 | Sale | 18.23 | 4,000 | 72,924 | 42,214 | Dec 06 05:34 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Mar 15 | Sale | 16.16 | 3,500 | 56,549 | 46,214 | Mar 16 06:25 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 21 | Option Exercise | 5.70 | 5,625 | 32,062 | 44,408 | Mar 06 08:24 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Feb 21 | Option Exercise | 5.70 | 5,625 | 32,062 | 44,408 | Mar 06 08:18 PM |
QDEL | TAMERIUS JOHN | SVP - Clinical/Reg Affairs | Aug 09 | Buy | 13.25 | 750 | 9,936 | 38,783 | Aug 10 06:04 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite